OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company discovering and developing small-molecule precision medicines for cancers and other diseases driven by specific mutations. Its research uses structure-based drug design, medicinal chemistry, X-ray crystallography and computational… From the company’s description.
In fiscal 2025, OnKure Therapeutics, Inc. reported a net loss of $59.52M. Operations used $51.83M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OnKure Therapeutics, Inc. does
In the company’s own words
OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company discovering and developing small-molecule precision medicines for cancers and other diseases driven by specific mutations. Its research uses structure-based drug design, medicinal chemistry, X-ray crystallography and computational chemistry to develop inhibitors intended to target mutated proteins while sparing their normal forms. The lead candidate, orally administered OKI-219, selectively inhibits PI3Kα with the H1047R mutation and is being evaluated in a Phase 1 trial in patients with advanced solid tumors, including breast cancer. Trial regimens include monotherapy and combinations with fulvestrant, ribociclib, trastuzumab and tucatinib, for patients with defined breast cancer subtypes. The company also pursues discovery programs for inhibitors targeting other common PI3Kα mutations and for PI3Kα-related vascular malformations. It retains worldwide rights to its programs and plans to pursue development and commercialization independently or with partners. The company has no products approved for commercial sale and has not generated product sales revenue.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOULDER, CO
- Fiscal year end
- December
- CIK
- 1637715
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OnKure Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OnKure Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OnKure Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OnKure Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OnKure Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”